To test whether the predictive value of the 18 upregulated genes we identified is specific to the ER+/HER2- breast cancer, we tested the predictive power of each gene also in HER2+/ER- and triple-negative breast cancers (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.